Cara could rise 'well past the mid-$20s' on good KALM-1 data, says StifelStifel analyst Annabel Samimy noted that Cara Therapeutics should be reporting its first pivotal readout of Phase 3 KALM-1 data for CKD-associated pruritus in the hemodialysis population within weeks and she believes the share "could move well past the mid-$20s" on a positive outcome. The analyst, who applies a 75% probability of success to Korsuva in CKD-associated pruritus, keeps a Buy rating and $26 price target on Cara shares and would be a buyer ahead of the data.Read more at: (source)https://thefly.com/landingPage...Tiger's Take: $CARA On our trading list, a medium size biotech with some potential. Does have a good amount of risk also. Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.